Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs - Trial NCT04943588
Access comprehensive clinical trial information for NCT04943588 through Pure Global AI's free database. This phase not specified trial is sponsored by Queen Mary University of London and is currently Not yet recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 25000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Queen Mary University of London
Timeline & Enrollment
N/A
Jul 01, 2021
Jan 01, 2023
Primary Outcome
SVR,Incidence of new infections,Incidence of re-infection
Summary
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by
 measuring effectiveness of Pakistan-government sponsored current therapies, emergence of
 viral resistance, consequences of infection (chiefly liver cancer) and through developing
 models, based on incidence data, determine the proportion of people who need curative
 treatment to eliminate HCV, and assess whether targeting can optimise this.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04943588
Non-Device Trial